Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Lancet Neurol. 2021 Apr;20(4):316-326. doi: 10.1016/S1474-4422(21)00023-5. Epub 2021 Mar 17.
China has approximately 10 million people with epilepsy. There is a vast epilepsy treatment gap in China, mainly driven by deficiencies in health-care delivery and social discrimination resulting from cultural beliefs about epilepsy. WHO's Global Campaign Against Epilepsy project in China showed that it was possible to treat epilepsy in primary care settings, which was a notable milestone. The China Association Against Epilepsy has been a necessary force to stimulate interest in epilepsy care and research by the medical and scientific community. Nearly 20 different anti-seizure medications are now available in China. Non-pharmacological options are also available, but there are still unmet needs for epilepsy management. The Chinese epilepsy research portfolio is varied, but the areas in which there are the most concentrated focus and expertise are epidemiology and clinical research. The challenges for further improvement in delivering care for people with epilepsy in China are primarily related to public health and reducing inequalities within this vast country.
中国约有 1000 万癫痫患者。中国存在巨大的癫痫治疗缺口，主要原因是医疗服务提供不足以及文化信仰导致的社会歧视。世界卫生组织在中国开展的全球癫痫防治项目表明，在基层医疗保健环境中治疗癫痫是可能的，这是一个显著的里程碑。中国抗癫痫协会一直是激发医学和科学界对癫痫护理和研究兴趣的必要力量。目前，中国有近 20 种抗癫痫药物。也有非药物治疗选择，但癫痫管理仍存在未满足的需求。中国的癫痫研究组合多样，但在流行病学和临床研究领域的关注度和专业知识最为集中。进一步改善中国癫痫患者护理的挑战主要与公共卫生以及减少这个幅员辽阔国家内部的不平等有关。
